Publications

• Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis of Esketamine and Respiratory Depression.Chepke C, Shelton R, Sanacora G, Doherty T, Tsytsik P, Parker N. Int J Neuropsychopharmacol. 2024 Nov 29; 2024 Nov 29. PMID: 39611487.
• Effect of Esketamine Nasal Spray on Cognition in Patients With Treatment-Resistant Depression: Results From Four Phase 3 Studies.Morrison RL, Singh J, Daly E, Fedgchin M, Ochs-Ross R, Karcher K, Lane R, Cooper K, Sanacora G, Maruff P, Drevets WC. Int J Neuropsychopharmacol. 2024 Nov 1. PMID: 39514643.
• The genetics of severe depression.Franklin CE, Achtyes E, Altinay M, Bailey K, Bhati MT, Carr BR, Conroy SK, Husain MM, Khurshid KA, Lencz T, McDonald WM, Mickey BJ, Murrough J, Nestor S, Nickl-Jockschat T, Nikayin S, Reeves K, Reti IM, Selek S, Sanacora G, Trapp NT, Viswanath B, Wright JH, Sullivan P, Zandi PP, Potash JB. Mol Psychiatry. 2024 Oct 15; 2024 Oct 15. PMID: 39406997.
• Efficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting.Santucci MC, Ansari M, Nikayin S, Radhakrishnan R, Rhee TG, Wilkinson ST. J Clin Psychiatry. 2024 Oct 2; 2024 Oct 2. PMID: 39361411.
• Deficits in prefrontal metabotropic glutamate receptor 5 are associated with functional alterations during emotional processing in bipolar disorder.Asch RH, Worhunsky PD, Davis MT, Holmes SE, Cool R, Boster S, Carson RE, Blumberg HP, Esterlis I. J Affect Disord. 2024 Sep 15; 2024 Jun 13. PMID: 38876317.
• Blood pressure changes during ketamine infusion for the treatment of depression.Ansari M, Pittman B, Tylee DS, Ostroff R, Wilkinson ST, Nikayin S. Gen Hosp Psychiatry. 2024 Sep-Oct; 2024 Jul 4. PMID: 38991311.
• Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial.Jha MK, Wilkinson ST, Krishnan K, Collins KA, Sanacora G, Murrough J, Goes F, Altinay M, Aloysi A, Asghar-Ali A, Barnett B, Chang L, Costi S, Malone D, Nikayin S, Nissen SE, Ostroff R, Reti I, Wolski K, Wang D, Hu B, Mathew SJ, Anand A. JAMA Netw Open. 2024 Jun 3; 2024 Jun 3. PMID: 38916891.
• Depression - Advanced Treatments for Treatment-Resistant Depression.Cristancho M, Fava M, Ingelfinger J, Nikayin S, Sanacora G. N Engl J Med. 2024 May 30. PMID: 38810184.
• Depression - Treatment Options and Managing Depression in Primary Care.Anderson E, Crawford CM, Fava M, Ingelfinger J, Sanacora G, Scott-Vernaglia S, Teel J. N Engl J Med. 2024 May 16. PMID: 38749042.
• Depression - Understanding, Identifying, and Diagnosing.Anderson E, Crawford CM, Fava M, Ingelfinger J, Nikayin S, Sanacora G, Scott-Vernaglia S, Teel J. N Engl J Med. 2024 May 2. PMID: 38692291.
• Author Correction: Synaptic loss and its association with symptom severity in Parkinson's disease.Holmes SE, Honhar P, Tinaz S, Naganawa M, Hilmer AT, Gallezot JD, Dias M, Yang Y, Toyonaga T, Esterlis I, Mecca A, Van Dyck C, Henry S, Ropchan J, Nabulsi N, Louis ED, Comley R, Finnema SJ, Carson RE, Matuskey D. NPJ Parkinsons Dis. 2024 Mar 12; 2024 Mar 12. PMID: 38472206.
• The Rapidly Shifting Ketamine Landscape in the US.Wilkinson ST, Palamar JJ, Sanacora G. JAMA Psychiatry. 2024 Mar 1. PMID: 38170542.
• Synaptic loss and its association with symptom severity in Parkinson's disease.Holmes SE, Honhar P, Tinaz S, Naganawa M, Hilmer AT, Gallezot JD, Dias M, Yang Y, Toyonaga T, Esterlis I, Mecca A, Van Dyck C, Henry S, Ropchan J, Nabulsi N, Louis ED, Comley R, Finnema SJ, Carson RE, Matuskey D. NPJ Parkinsons Dis. 2024 Feb 24; 2024 Feb 24. PMID: 38402233.
• Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments.Krystal JH, Kaye AP, Jefferson S, Girgenti MJ, Wilkinson ST, Sanacora G, Esterlis I. Proc Natl Acad Sci U S A. 2023 Dec 5; 2023 Nov 27. PMID: 38011560.
• Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocol.Kitay BM, Murphy E, Macaluso M, Corlett PR, Hershenberg R, Joormann J, Martinez-Kaigi V, Nikayin S, Rhee TG, Sanacora G, Shelton RC, Thase ME, Wilkinson ST. Psychiatry Res. 2023 Dec; 2023 Oct 30. PMID: 37935086.
• Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders.Rhee TG, Davoudian PA, Sanacora G, Wilkinson ST. Drug Discov Today. 2023 Dec; 2023 Nov 2. PMID: 37925136.
• Prefrontal cortex astroglia modulate anhedonia-like behavior.Codeluppi SA, Xu M, Bansal Y, Lepack AE, Duric V, Chow M, Muir J, Bagot RC, Licznerski P, Wilber SL, Sanacora G, Sibille E, Duman RS, Pittenger C, Banasr M. Mol Psychiatry. 2023 Nov; 2023 Sep 11. PMID: 37696873.
• Using latent profile analyses to classify subjects with anhedonia based on reward-related measures obtained in the FAST-MAS study.Darrow SM, Pizzagalli DA, Smoski M, Mathew SJ, Nurnberger J Jr, Lisanby SH, Iosifescu D, Murrough JW, Yang H, Weiner RD, Sanacora G, Keefe RSE, Song A, Goodman W, Whitton AE, Potter WZ, Krystal AD. J Affect Disord. 2023 Oct 15; 2023 Jul 17. PMID: 37467805.
• Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions.McIntyre RS, Alsuwaidan M, Baune BT, Berk M, Demyttenaere K, Goldberg JF, Gorwood P, Ho R, Kasper S, Kennedy SH, Ly-Uson J, Mansur RB, McAllister-Williams RH, Murrough JW, Nemeroff CB, Nierenberg AA, Rosenblat JD, Sanacora G, Schatzberg AF, Shelton R, Stahl SM, Trivedi MH, Vieta E, Vinberg M, Williams N, Young AH, Maj M. World Psychiatry. 2023 Oct. PMID: 37713549.
• Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, Kakar R, Hassman M, Trivedi RP, Robison R, Gukasyan N, Nayak SM, Hu X, O'Donnell KC, Kelmendi B, Sloshower J, Penn AD, Bradley E, Kelly DF, Mletzko T, Nicholas CR, Hutson PR, Tarpley G, Utzinger M, Lenoch K, Warchol K, Gapasin T, Davis MC, Nelson-Douthit C, Wilson S, Brown C, Linton W, Ross S, Griffiths RR. JAMA. 2023 Sep 5. PMID: 37651119.
• The Intricate Interaction Between Expectations and Therapeutic Outcomes of Psychedelic Agents.Colloca L, Nikayin S, Sanacora G. JAMA Psychiatry. 2023 Sep 1. PMID: 37405764.
• Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study.Castro M, Wilkinson ST, Al Jurdi RK, Petrillo MP, Zaki N, Borentain S, Fu DJ, Turkoz I, Sun L, Brown B, Cabrera P. CNS Drugs. 2023 Aug; 2023 Aug 9. PMID: 37558912.
• Treatment response to esketamine nasal spray in patients with major depressive disorder and acute suicidal ideation or behavior without evidence of early response: a pooled post hoc analysis of ASPIRE.Turkoz I, Lopena O, Salvadore G, Sanacora G, Shelton R, Fu DJ. CNS Spectr. 2023 Aug; 2022 Jul 29. PMID: 35904046.
• Trends in Illicit Ketamine Seizures in the US From 2017 to 2022.Palamar JJ, Wilkinson ST, Carr TH, Rutherford C, Cottler LB. JAMA Psychiatry. 2023 Jul 1. PMID: 37223891.
• Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study.Zaki N, Chen LN, Lane R, Doherty T, Drevets WC, Morrison RL, Sanacora G, Wilkinson ST, Popova V, Fu DJ. Neuropsychopharmacology. 2023 Jul; 2023 May 12. PMID: 37173512.
• Prefrontal Cortex Astroglia Modulate Anhedonia-like Behavior.Codeluppi SA, Xu M, Bansal Y, Lepack AE, Duric V, Chow M, Muir J, Bagot RC, Licznerski P, Wilber SL, Sanacora G, Sibille E, Duman RS, Pittenger C, Banasr M. Res Sq. 2023 Jun 30; 2023 Jun 30. PMID: 37461693.
• Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.Anand A, Mathew SJ, Sanacora G, Murrough JW, Goes FS, Altinay M, Aloysi AS, Asghar-Ali AA, Barnett BS, Chang LC, Collins KA, Costi S, Iqbal S, Jha MK, Krishnan K, Malone DA, Nikayin S, Nissen SE, Ostroff RB, Reti IM, Wilkinson ST, Wolski K, Hu B. N Engl J Med. 2023 Jun 22; 2023 May 24. PMID: 37224232.
• Differences in Quantification of the Metabotropic Glutamate Receptor 5 Across Bipolar Disorder and Major Depressive Disorder.Holmes SE, Asch RH, Davis MT, DellaGioia N, Pashankar N, Gallezot JD, Nabulsi N, Matuskey D, Sanacora G, Carson RE, Blumberg HP, Esterlis I. Biol Psychiatry. 2023 Jun 15; 2022 Nov 8. PMID: 36764853.
• Candidate biomarkers in psychiatric disorders: state of the field.Abi-Dargham A, Moeller SJ, Ali F, DeLorenzo C, Domschke K, Horga G, Jutla A, Kotov R, Paulus MP, Rubio JM, Sanacora G, Veenstra-VanderWeele J, Krystal JH. World Psychiatry. 2023 Jun. PMID: 37159365.
• The Role of Psychotherapy in the Management of Treatment-Resistant Depression.Rogan T, Wilkinson ST. Psychiatr Clin North Am. 2023 Jun; 2023 Mar 15. PMID: 37149349.
• Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study.Leal GC, Souza-Marques B, Mello RP, Bandeira ID, Caliman-Fontes AT, Carneiro BA, Faria-Guimarães D, Guerreiro-Costa LNF, Jesus-Nunes AP, Silva SS, Lins-Silva DH, Fontes MA, Alves-Pereira R, Cordeiro V, Rugieri-Pacheco S, Santos-Lima C, Correia-Melo FS, Vieira F, Sanacora G, Lacerda ALT, Quarantini LC. J Affect Disord. 2023 Jun 1; 2023 Mar 4. PMID: 36871913.
• Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray.Turkoz I, Nelson JC, Wilkinson ST, Borentain S, Macaluso M, Trivedi MH, Williamson D, Sheehan JJ, Salvadore G, Singh J, Daly E. Psychiatry Res. 2023 May; 2023 Mar 16. PMID: 37019044.
• Pharmacological and Somatic Treatment Effects on Suicide in Adults: A Systematic Review and Meta-Analysis.Wilkinson ST, Trujillo Diaz D, Rupp ZW, Kidambi A, Ramirez KL, Flores JM, Avila-Quintero VJ, Rhee TG, Olfson M, Bloch MH. Focus (Am Psychiatr Publ). 2023 Apr; 2023 Apr 14. PMID: 37201149.
• Linking resting-state network fluctuations with systems of coherent synaptic density: A multimodal fMRI and (11)C-UCB-J PET study.Fang XT, Volpi T, Holmes SE, Esterlis I, Carson RE, Worhunsky PD. Front Hum Neurosci. 2023; 2023 Feb 23. PMID: 36908710.
• Prophylactic Efficacy of Riluzole against Anxiety- and Depressive-Like Behaviors in Two Rodent Stress Models.Bansal Y, Fee C, Misquitta KA, Codeluppi SA, Sibille E, Berman RM, Coric V, Sanacora G, Banasr M. Complex Psychiatry. 2023 Jan-Dec; 2023 Feb 3. PMID: 37101541.
• Effects of Electroconvulsive Therapy on Functional Outcomes Among Medicare Patients With Comorbid Depression and Dementia: A Nationwide 1-Year Follow-Up Study.Wilkinson ST, Sint K, Forester BP, Rhee TG. J Clin Psychiatry. 2023 Jan 25; 2023 Jan 25. PMID: 36700843.
• Imaging synaptic density in depression.Holmes SE, Abdallah C, Esterlis I. Neuropsychopharmacology. 2023 Jan; 2022 Jun 29. PMID: 35768568.
• Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode: A Systematic Review and Meta-analysis.Rhee TG, Shim SR, Forester BP, Nierenberg AA, McIntyre RS, Papakostas GI, Krystal JH, Sanacora G, Wilkinson ST. JAMA Psychiatry. 2022 Dec 1. PMID: 36260324.
• International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators.Price RB, Kissel N, Baumeister A, Rohac R, Woody ML, Ballard ED, Zarate CA Jr, Deakin W, Abdallah CG, Feder A, Charney DS, Grunebaum MF, Mann JJ, Mathew SJ, Gallagher B, McLoughlin DM, Murrough JW, Muthukumaraswamy S, McMillan R, Sumner R, Papakostas G, Fava M, Hock R, Phillips JL, Blier P, Shiroma P, Šóš P, Su TP, Chen MH, Tiger M, Lundberg J, Wilkinson ST, Wallace ML. Mol Psychiatry. 2022 Dec; 2022 Sep 7. PMID: 36071111.
• At-home ketamine; still a lot to learn.Wilkinson ST, Sanacora G. J Affect Disord. 2022 Dec 1; 2022 Sep 5. PMID: 36067887.
• Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study.Feeney A, Hoeppner BB, Freeman MP, Flynn M, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, DeBattista C, Ionescu DF, Cusin C, Papakostas GI, Jha MK, Fava M. J Clin Psychiatry. 2022 Nov 14; 2022 Nov 14. PMID: 36383742.
• A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Nonsuicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine.Bloomfield-Clagett B, Ballard ED, Greenstein DK, Wilkinson ST, Grunebaum MF, Murrough JW, Mathew SJ, Phillips JL, Fava M, Sanacora G, Zarate CA. Int J Neuropsychopharmacol. 2022 Oct 25. PMID: 35994774.
• Ketamine in the Real World: Where Do We Go From Here?Wilkinson ST. J Clin Psychiatry. 2022 Sep 14; 2022 Sep 14. PMID: 36112579.
• Brain-phenotype models fail for individuals who defy sample stereotypes.Greene AS, Shen X, Noble S, Horien C, Hahn CA, Arora J, Tokoglu F, Spann MN, Carrión CI, Barron DS, Sanacora G, Srihari VH, Woods SW, Scheinost D, Constable RT. Nature. 2022 Sep; 2022 Aug 24. PMID: 36002572.
• Catatonia After COVID-19: A Case Series.Nikayin S, Chaffkin J, Ostroff RB. J ECT. 2022 Sep 1; 2022 Mar 1. PMID: 35220361.
• Evaluation of the Trajectory of Depression Severity With Ketamine and Esketamine Treatment in a Clinical Setting.Nikayin S, Rhee TG, Cunningham ME, de Fontnouvelle CA, Ostroff RB, Sanacora G, Wilkinson ST. JAMA Psychiatry. 2022 Jul 1. PMID: 35544190.
• Long-term safety of ketamine and esketamine in treatment of depression.Nikayin S, Murphy E, Krystal JH, Wilkinson ST. Expert Opin Drug Saf. 2022 Jun; 2022 Apr 19. PMID: 35416105.
• A Novel Biomarker of Neuronal Glutamate Metabolism in Nonhuman Primates Using Localized (1)H-Magnetic Resonance Spectroscopy: Development and Effects of BNC375, an α7 Nicotinic Acetylcholine Receptor Positive Allosteric Modulator.Miller CO, Gantert LT, Previs SF, Chen Y, Anderson KD, Thomas JM, Sanacora G, Uslaner JM, Rothman DL, Mason GF. Biol Psychiatry Cogn Neurosci Neuroimaging. 2022 Jun; 2020 Sep 29. PMID: 33309567.
• An Update on Community Ketamine Practices.O'Brien B, Wilkinson ST, Mathew SJ. Am J Psychiatry. 2022 May. PMID: 35491568.
• A Choice-Based Conjoint Analysis of the Psychiatrist Decision-Making Process Used in Determining When to Discharge Adults With Major Depressive Disorder Hospitalized for Active Suicidal Ideation With Intent.Voelker J, Wilkinson ST, Katz EG, Nash AI, Daly E, Ali A, Lovink A, Stahl J, Desai A, Kuvadia H, Neslusan C, Sheehan JJ. J Nerv Ment Dis. 2022 May 1. PMID: 34937847.
• Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study.Ochs-Ross R, Wajs E, Daly EJ, Zhang Y, Lane R, Lim P, Drevets WC, Steffens DC, Sanacora G, Jamieson C, Hough D, Manji H, Singh JB. Am J Geriatr Psychiatry. 2022 May; 2021 Oct 6. PMID: 34750057.
• mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression.Averill LA, Averill CL, Gueorguieva R, Fouda S, Sherif M, Ahn KH, Ranganathan M, D'Souza DC, Southwick SM, Sanacora G, Duman RS, Krystal JH, Abdallah CG. J Affect Disord. 2022 Apr 15; 2022 Jan 29. PMID: 35101523.
• Prefrontal Glutamate Neurotransmission in PTSD: A Novel Approach to Estimate Synaptic Strength in Vivo in Humans.Averill LA, Jiang L, Purohit P, Coppoli A, Averill CL, Roscoe J, Kelmendi B, De Feyter HM, de Graaf RA, Gueorguieva R, Sanacora G, Krystal JH, Rothman DL, Mason GF, Abdallah CG. Chronic Stress (Thousand Oaks). 2022 Jan-Dec; 2022 Apr 11. PMID: 35434443.
• Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.Dwyer JB, Landeros-Weisenberger A, Johnson JA, Londono Tobon A, Flores JM, Nasir M, Couloures K, Sanacora G, Bloch MH. Focus (Am Psychiatr Publ). 2022 Apr; 2022 Apr 22. PMID: 37153136.
• Imaging the effect of ketamine on synaptic density (SV2A) in the living brain.Holmes SE, Finnema SJ, Naganawa M, DellaGioia N, Holden D, Fowles K, Davis M, Ropchan J, Emory P, Ye Y, Nabulsi N, Matuskey D, Angarita GA, Pietrzak RH, Duman RS, Sanacora G, Krystal JH, Carson RE, Esterlis I. Mol Psychiatry. 2022 Apr; 2022 Feb 15. PMID: 35165397.
• Advanced training in interventional psychiatry.Nikayin S, Taylor JJ, Ostroff RB. J Neurol Sci. 2022 Mar 15; 2021 Dec 16. PMID: 34974201.
• Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review.Bandeira ID, Lins-Silva DH, Cavenaghi VB, Dorea-Bandeira I, Faria-Guimarães D, Barouh JL, Jesus-Nunes AP, Beanes G, Souza LS, Leal GC, Sanacora G, Miguel EC, Sampaio AS, Quarantini LC. Harv Rev Psychiatry. 2022 Mar-Apr 01. PMID: 35267254.
• The stressed synapse 2.0: pathophysiological mechanisms in stress-related neuropsychiatric disorders.Sanacora G, Yan Z, Popoli M. Nat Rev Neurosci. 2022 Feb; 2021 Dec 10. PMID: 34893785.
• Pharmacological and somatic treatment effects on suicide in adults: A systematic review and meta-analysis.Wilkinson ST, Trujillo Diaz D, Rupp ZW, Kidambi A, Ramirez KL, Flores JM, Avila-Quintero VJ, Rhee TG, Olfson M, Bloch MH. Depress Anxiety. 2022 Feb; 2021 Nov 11. PMID: 34762330.
• Lower synaptic density is associated with psychiatric and cognitive alterations in obesity.Asch RH, Holmes SE, Jastreboff AM, Potenza MN, Baldassarri SR, Carson RE, Pietrzak RH, Esterlis I. Neuropsychopharmacology. 2022 Jan; 2021 Jul 22. PMID: 34294874.
• Twenty-year trends in use of electroconvulsive therapy among homeless and domiciled veterans with mental illness.Tsai J, Szymkowiak D, Wilkinson ST, Holtzheimer PE. CNS Spectr. 2021 Dec 13; 2021 Dec 13. PMID: 34895380.
• Association of ECT With Risks of All-Cause Mortality and Suicide in Older Medicare Patients.Rhee TG, Sint K, Olfson M, Gerhard T, H Busch S, Wilkinson ST. Am J Psychiatry. 2021 Dec; 2021 Sep 10. PMID: 34503341.
• Utilization of Electroconvulsive Therapy for Older Homeless Adults Covered by Medicare.Wilkinson ST, Rhee TG, Tsai J. Psychiatr Q. 2021 Dec; 2021 Sep 1. PMID: 34468909.
• The Impact of Depression on Outcomes in Patients With Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT Trial.Chouairi F, Fuery MA, Mullan CW, Caraballo C, Sen S, Maulion C, Wilkinson ST, Surti T, McCullough M, Miller PE, Pacor J, Leifer ES, Felker GM, Velazquez EJ, Fiuzat M, O'Connor CM, Januzzi JL, Desai NR, Ahmad T. J Card Fail. 2021 Dec; 2021 Jun 22. PMID: 34166799.
• Correction to: Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS).Pizzagalli DA, Smoski M, Ang YS, Whitton AE, Sanacora G, Mathew SJ, Nurnberger J Jr, Lisanby SH, Iosifescu DV, Murrough JW, Yang H, Weiner RD, Calabrese JR, Goodman W, Potter WZ, Krystal AD. Neuropsychopharmacology. 2021 Nov. PMID: 34389811.
• Evaluating the Role of Ketamine/Esketamine in the Management of Major Depressive Disorder with Suicide Risk.Nikayin S, Sanacora G. CNS Drugs. 2021 Oct; 2021 Sep 7. PMID: 34491545.
• Mental Health Care Resource Utilization and Barriers to Receiving Mental Health Services Among US Adults With a Major Depressive Episode and Suicidal Ideation or Behavior With Intent.Voelker J, Cai Q, Daly E, Connolly N, Pesa J, Sheehan JJ, Wilkinson ST. J Clin Psychiatry. 2021 Sep 14; 2021 Sep 14. PMID: 34529898.
• Cell-type specific modulation of NMDA receptors triggers antidepressant actions.Pothula S, Kato T, Liu RJ, Wu M, Gerhard D, Shinohara R, Sliby AN, Chowdhury GMI, Behar KL, Sanacora G, Banerjee P, Duman RS. Mol Psychiatry. 2021 Sep; 2020 Jun 2. PMID: 32488125.
• Identifying brain networks in synaptic density PET ((11)C-UCB-J) with independent component analysis.Fang XT, Toyonaga T, Hillmer AT, Matuskey D, Holmes SE, Radhakrishnan R, Mecca AP, van Dyck CH, D'Souza DC, Esterlis I, Worhunsky PD, Carson RE. Neuroimage. 2021 Aug 15; 2021 May 15. PMID: 34000404.
• The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study.Feeney A, Hock RS, Freeman MP, Flynn M, Hoeppner B, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Fava M, Papakostas GI. Eur Neuropsychopharmacol. 2021 Aug; 2021 Jun 3. PMID: 34090255.
• Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response: A Pooled Post Hoc Analysis of the TRANSFORM Studies.Turkoz I, Daly E, Singh J, Lin X, Tymofyeyev Y, Williamson D, Salvadore G, Nash AI, Macaluso M, Wilkinson ST, Nelson JC. J Clin Psychiatry. 2021 Jul 20; 2021 Jul 20. PMID: 34288609.
• Macro- and Microscale Stress-Associated Alterations in Brain Structure: Translational Link With Depression.Banasr M, Sanacora G, Esterlis I. Biol Psychiatry. 2021 Jul 15; 2021 Apr 16. PMID: 34001371.
• A Potential Case of Acute Ketamine Withdrawal: Clinical Implications for the Treatment of Refractory Depression.Roxas N, Ahuja C, Isom J, Wilkinson ST, Capurso N. Am J Psychiatry. 2021 Jul. PMID: 34270337.
• Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions.Levey DF, Stein MB, Wendt FR, Pathak GA, Zhou H, Aslan M, Quaden R, Harrington KM, Nuñez YZ, Overstreet C, Radhakrishnan K, Sanacora G, McIntosh AM, Shi J, Shringarpure SS, Concato J, Polimanti R, Gelernter J. Nat Neurosci. 2021 Jul; 2021 May 27. PMID: 34045744.
• Barriers to the Implementation of Electroconvulsive Therapy (ECT): Results From a Nationwide Survey of ECT Practitioners.Wilkinson ST, Kitay BM, Harper A, Rhee TG, Sint K, Ghosh A, Lopez MO, Saenz S, Tsai J. Psychiatr Serv. 2021 Jul 1; 2021 May 11. PMID: 33971727.
• Emerging Therapeutics Based on the Amino Acid Neurotransmitter System: An Update on the Pharmaceutical Pipeline for Mood Disorders.Hecking J, Davoudian PA, Wilkinson ST. Chronic Stress (Thousand Oaks). 2021 Jan-Dec; 2021 Jun 2. PMID: 34124495.
• Absence seizures and their relationship to depression and anxiety: Evidence for bidirectionality.Gruenbaum BF, Sandhu MRS, Bertasi RAO, Bertasi TGO, Schonwald A, Kurup A, Gruenbaum SE, Freedman IG, Funaro MC, Blumenfeld H, Sanacora G. Epilepsia. 2021 May; 2021 Mar 10. PMID: 33751566.
• Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, Brietzke E, Dodd S, Gorwood P, Ho R, Iosifescu DV, Lopez Jaramillo C, Kasper S, Kratiuk K, Lee JG, Lee Y, Lui LMW, Mansur RB, Papakostas GI, Subramaniapillai M, Thase M, Vieta E, Young AH, Zarate CA Jr, Stahl S. Am J Psychiatry. 2021 May 1; 2021 Mar 17. PMID: 33726522.
• Repetitive and Self-injurious Behaviors in Children with Cornelia de Lange Syndrome.Srivastava S, Clark B, Landy-Schmitt C, Offermann EA, Kline AD, Wilkinson ST, Grados MA. J Autism Dev Disord. 2021 May. PMID: 32809170.
• Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.Dwyer JB, Landeros-Weisenberger A, Johnson JA, Londono Tobon A, Flores JM, Nasir M, Couloures K, Sanacora G, Bloch MH. Am J Psychiatry. 2021 Apr 1; 2021 Mar 3. PMID: 33653121.
• Intravenous arketamine for treatment-resistant depression: open-label pilot study.Leal GC, Bandeira ID, Correia-Melo FS, Telles M, Mello RP, Vieira F, Lima CS, Jesus-Nunes AP, Guerreiro-Costa LNF, Marback RF, Caliman-Fontes AT, Marques BLS, Bezerra MLO, Dias-Neto AL, Silva SS, Sampaio AS, Sanacora G, Turecki G, Loo C, Lacerda ALT, Quarantini LC. Eur Arch Psychiatry Clin Neurosci. 2021 Apr; 2020 Feb 20. PMID: 32078034.
• Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial.Wilkinson ST, Rhee TG, Joormann J, Webler R, Ortiz Lopez M, Kitay B, Fasula M, Elder C, Fenton L, Sanacora G. Psychother Psychosom. 2021; 2021 Jun 29. PMID: 34186531.
• Factors associated with health-related quality of life in patients with cirrhosis: a systematic review.Rabiee A, Ximenes RO, Nikayin S, Hickner A, Juthani P, Rosen RH, Garcia-Tsao G. Liver Int. 2021 Jan; 2020 Nov 2. PMID: 32998172.
• Ketamine Normalizes the Structural Alterations of Inferior Frontal Gyrus in Depression.Dai D, Lacadie CM, Holmes SE, Cool R, Anticevic A, Averill C, Abdallah C, Esterlis I. Chronic Stress (Thousand Oaks). 2020 Jan-Dec; 2020 Dec 22. PMID: 33426409.
• Prevalence of Treatment for Depression Among US Adults Who Screen Positive for Depression, 2007-2016.Rhee TG, Wilkinson ST, Steffens DC, Rosenheck RA, Olfson M. JAMA Psychiatry. 2020 Nov 1. PMID: 32609306.
• Changes in pharmacotherapeutic approaches in the treatment of bipolar disorder by primary care physicians.Rhee TG, Olfson M, Wilkinson ST. Gen Hosp Psychiatry. 2020 Nov-Dec; 2020 Mar 14. PMID: 32184005.
• Measuring the effects of ketamine on mGluR5 using [(18)F]FPEB and PET.Holmes SE, Gallezot JD, Davis MT, DellaGioia N, Matuskey D, Nabulsi N, Krystal JH, Javitch JA, DeLorenzo C, Carson RE, Esterlis I. J Cereb Blood Flow Metab. 2020 Nov; 2019 Nov 19. PMID: 31744389.
• Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS).Pizzagalli DA, Smoski M, Ang YS, Whitton AE, Sanacora G, Mathew SJ, Nurnberger J Jr, Lisanby SH, Iosifescu DV, Murrough JW, Yang H, Weiner RD, Calabrese JR, Goodman W, Potter WZ, Krystal AD. Neuropsychopharmacology. 2020 Sep; 2020 Jun 16. PMID: 32544925.
• 20-Year Trends in the Pharmacologic Treatment of Bipolar Disorder by Psychiatrists in Outpatient Care Settings.Rhee TG, Olfson M, Nierenberg AA, Wilkinson ST. Am J Psychiatry. 2020 Aug 1; 2020 Apr 21. PMID: 32312111.
• Characterization of the Quality of Electroconvulsive Therapy Among Older Medicare Beneficiaries.Rhee TG, Olfson M, Sint K, Wilkinson ST. J Clin Psychiatry. 2020 Jul 7; 2020 Jul 7. PMID: 32659875.
• Exploring the Psychiatrist-Industry Financial Relationship: Insight from the Open Payment Data of Centers for Medicare and Medicaid Services.Rhee TG, Wilkinson ST. Adm Policy Ment Health. 2020 Jul. PMID: 31916072.
• Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI. Mol Psychiatry. 2020 Jul. PMID: 30617276.
• Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI. Mol Psychiatry. 2020 Jul; 2018 Oct 3. PMID: 30283029.
• Early life stress and glutamate neurotransmission in major depressive disorder.Averill LA, Abdallah CG, Fenton LR, Fasula MK, Jiang L, Rothman DL, Mason GF, Sanacora G. Eur Neuropsychopharmacol. 2020 Jun; 2020 May 15. PMID: 32418842.
• Is This Where We Stand After Decades of Research to Develop More Personalized Treatments for Depression?Sanacora G. JAMA Psychiatry. 2020 Jun 1. PMID: 32074267.
• Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I).Fu DJ, Ionescu DF, Li X, Lane R, Lim P, Sanacora G, Hough D, Manji H, Drevets WC, Canuso CM. J Clin Psychiatry. 2020 May 12; 2020 May 12. PMID: 32412700.
• Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder.Freeman MP, Hock RS, Papakostas GI, Judge H, Cusin C, Mathew SJ, Sanacora G, Iosifescu DV, DeBattista C, Trivedi MH, Fava M. J Clin Psychopharmacol. 2020 May/Jun. PMID: 32332464.
• A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia.Krystal AD, Pizzagalli DA, Smoski M, Mathew SJ, Nurnberger J Jr, Lisanby SH, Iosifescu D, Murrough JW, Yang H, Weiner RD, Calabrese JR, Sanacora G, Hermes G, Keefe RSE, Song A, Goodman W, Szabo ST, Whitton AE, Gao K, Potter WZ. Nat Med. 2020 May; 2020 Mar 30. PMID: 32231295.
• Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin.Abdallah CG, Averill LA, Gueorguieva R, Goktas S, Purohit P, Ranganathan M, Sherif M, Ahn KH, D'Souza DC, Formica R, Southwick SM, Duman RS, Sanacora G, Krystal JH. Neuropsychopharmacology. 2020 May; 2020 Feb 24. PMID: 32092760.
• Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).Wajs E, Aluisio L, Holder R, Daly EJ, Lane R, Lim P, George JE, Morrison RL, Sanacora G, Young AH, Kasper S, Sulaiman AH, Li CT, Paik JW, Manji H, Hough D, Grunfeld J, Jeon HJ, Wilkinson ST, Drevets WC, Singh JB. J Clin Psychiatry. 2020 Apr 28; 2020 Apr 28. PMID: 32316080.